Happytal, SAS

Happytal is a company focused on enhancing patient comfort and well-being during hospital stays through a comprehensive concierge service and personalized amenities delivery, enriching the overall healthcare experience. Founded in 2013, Happytal, based in Paris, France, specializes in improving patient experiences in hospital settings. The company has completed a total of 5 deals, with the most recent deal occurring on September 7, 2022, during which La Poste SA acquired Happytal. The latest funding round was a Series C, raising EUR 19.

988 mn, led by AXA Venture Partners. Romain Revellat, the founder, has a history in developing patient-centered solutions in healthcare. Happytal specializes in providing a comprehensive suite of services aimed at enhancing the comfort and well-being of patients during and after their hospital stays. Central to their offerings is an in-hospital concierge service that facilitates access to various amenities designed to improve the patient experience.

This includes the provision of products and services delivered directly to patient rooms, which allows for a more personalized hospital experience. Additionally, Happytal offers an online platform that supports patients post-discharge, catering to their needs and preferences as they transition back home. The company serves a diverse clientele, including patients, their families, and healthcare personnel, operating primarily within hospital environments across France and potentially expanding into other European markets. In 2023, Happytal generated revenue of EUR 20.

84 mn, with an EBITDA of EUR -4. 09 mn. The company utilizes a transactional revenue model, establishing partnerships with healthcare facilities to provide concierge services and online product delivery as part of the patient care experience. Happytal is focused on launching new products designed to enhance patient engagement and streamline services.

The company is exploring expansion into additional European markets by the end of 2024. Recent funding from the Series C round, amounting to EUR 19. 988 mn, will support these initiatives, particularly in developing new offerings and enhancing the platform for post-discharge support.